Sanwo-Olu opens SDGs multi-storey Sickle Cell Centre at LASUTH – Newstrends
Connect with us

Health

Sanwo-Olu opens SDGs multi-storey Sickle Cell Centre at LASUTH

Published

on

Sanwo-Olu opens SDGs multi-storey Sickle Cell Centre at LASUTH

Intervention will stem infant mortality rate — Orelope-Adefulire

Lagos State Governor Babajide Sanwo-Olu, on Friday, inaugurated the two-storey Paediatric Sickle Cell Centre sited in the Lagos State University Teaching Hospital (LASUTH), Ikeja.

The medical facility was donated by the Office of the Senior Special Assistant (SSA) to the President on Sustainable Development Goals (SDGs) occupied by Princess Adejoke Orelope-Adefulire.

Sanwo-Olu described the intervention as a “remarkable donation” strategic to the state’s healthcare value chain.

The governor said the project would scale up response time to cases and stem infant mortality.

He said, “This collaboration with the Office of the SSA to the President on SDGs is a testament to our collective commitment to improving care for children living with sickle cell diseases. “I acknowledge Princess Orelope-Adefulire for her vision and unwavering commitment to healthcare advancement that made this centre a reality.

“This will not only transform our healthcare landscape, it will also add to the number of child care facilities in Lagos.

“If we all work together, we can achieve a lot more together. This hospital will provide a comprehensive care that will include early diagnosis, advanced treatment and continuous management to children that are suffering the debilitating condition.

“The centre will also serve as a hub for research and education, which will foster and deeper understanding of the disease. More importantly, it will contribute to reducing infant mortality index.”

Sanwo-Olu said the facility would nurture an environment where children would get holistic care tailored to their individual needs, including medical treatment and psychological support.

The governor expressed appreciation to President Bola Ahmed Tinubu for finding Lagos worthy to benefit from the intervention.

He said the project had further reinforced the health vision of the President to enhance the nation’s capacity to meet global health coverage.

Minister of State for Health, Dr Tunji Alausa, described sickle cell as health burden on the nation.

He said the disease doesn’t affect carriers alone, it also places constraints on family members and community as a whole.

Alausa called for optima use of the facility adding that the centre would provide top tier care for patients and researchers.

He thanked the SSA to the President for her contributions to the health sector.

Mrs Orelope-Adefulire, a former Deputy Governor of Lagos, said sickle cell disease had impacted communities across the nation negatively, subjecting families to psychological torture.

This, she said, informed the priority accorded the development of modern medical care capability to address the growing cases.

The SSA said three million people are living with sickle cell disease in Nigeria, projecting precarious outlook for the country.

She said the President approved the initiative to further demonstrate his commitment to achieving all targets set in Goal 3, Target 2 of the SGDs and leave no one behind in the initiatives rolled out to address the challenges.

She said, “This intervention is a cardinal pillar of healthcare and empowerment in the Renewed Hope Agenda of the current administration. Knowledge and skill among the public health workers are critical to improving the care for sickle cell cases.

“Before now, LASUTH treated 45 out of 1,000 patients weekly due to constraints of space and facilities.

“This Sickle Cell Care Centre will contribute to the achievement of the Sustainable Development Goal 3, Target 2, which seek to end preventable deaths of newborns and children under five years of age, thereby reducing global burden to 25 per 1,000 by 2030. In Nigeria, our target is to achieve zero per 1,000 at the end of implementation period.”

She thanked President Bola Ahmed Tinubu for his leadership and commitment to the achievement of the SDGs through his administration’s Renewed Hope Agenda.

The SSA also hailed Governor Sanwo-Olu for his unwavering commitment to the socio-economic transformation of Lagos State and collective desire to achieve the SDGs.

LASUTH Chief Medical Director, Prof. Adetokunbo Fabanwo, said the facility would offer preventive and therapeutic care to child sufferers, thanking Orelope-Adefulire for supporting the teaching hospital with the project.

He said the centre would take off the burden of the Paediatric Unit in the teaching hospital, which was challenged by surging cases of child sufferers.

The new facility, he said, offers conducive environment for treatment.

“LASUTH is blessed with dedicated staff that look after children with sickle cell disease. In the new Centre, child patients will have the benefit of a conducive environment to be attended as out patients; those in need of a day or prolonged admission can also be admitted,” Prof. Fabanwo said.

Head of the Paediatrics, Haematology, Oncology Unit at LASUTH and Coordinator of the centre, Dr. Ijeoma Akinwumi, gave details of the activities that would be carried in the facility.

The Associate Professor of Paediatrics said the centre would cater for children between zero age and 18 years, giving them comprehensive care in their moments of crisis.

She said the centre is equipped to carry out diagnosis of sickle cell within 10 minutes.

She also said the units in the facility include multi-disciplinary unit, counseling unit, X-Ray therapy unit, laboratory and pharmacy.

“The centre is built with electronic record technology to manage medical records of patients from birth to adult,” she said.

Health

25 cholera cases recorded in Ogun, one dead

Published

on

25 cholera cases recorded in Ogun, one dead

The Ogun State Commissioner for Health, Tomi Coker on Monday, disclosed that the state has recorded 25 suspected cholera cases in seven local government areas in the state.

Coker explained that nine cases had been confirmed while one death was recorded.

She stated that the state epidemiology unit had been put on red alert during a press conference held at the Olusegun Osoba Press Centre, Governor’s office, Abeokuta.

The affected LGs are Ado Odo/Ota; Remo North; Odeda; Sagamu; Ijebu North; Ewekoro and Obafemi Owode.

Coker said that the Ministry is coordinating the outbreak response in conjunction with other stakeholders from the Ministry of Environment, Information and Education.

The Commissioner said that the treatment of cholera is free in all public health facilities across the State and that trained rapid teams across the 20 LGAs are prepared to respond to calls on these following lines; 08038642812; 07034214893 and 08084250881 on short notice.

She said, “As of today 24th, June 2024, the Ogun state has recorded 25 suspected cases of Cholera in 7 LGAs namely, Adoodo/Ota, Remo North, Odeda, Sagamu, Ijebu North, Ewekoro, and Obafemi Owode, with 9 confirmed case and unfortunately, one death.

READ ALSO:

“At inception, we received the alert on June 12, 2024, about the first two cases. Both cases tested positive with a Cholera rapid diagnostic kit and were managed at the State Hospital, Ota. The two cases had travel history to Lagos State 24 hours prior to presentation.

“Also, cholera test kits and other consumables needed for treatment have been distributed to all LGAs and designated treatment centres to ensure prompt diagnosis and treatment. The treatment of Cholera is free across all government facilities in Ogun State.”

She said that some Local Government Areas such as Abeokuta South, Abeokuta North, Ijebu North, Obafemi Owode, Ifo, and Ado-Odo/Ota have been identified to be high-risk areas.

She stated that the fluid movement of people from neighbouring states, especially Lagos, which is the epicentre of the cholera outbreak, has made the disease spread in border LGs areas of the State.

She equally said that cholera vaccines are not currently available in the state urging the citizens to adhere to precautionary measures to ward off this disease.

Speaking during the briefing, the Commissioner for Environment, Ola Oresanya, said that the state government has constructed over 60 public toilets across the State to address open defecation.

Oresanya said that the industry has improved on waste management collection across the state while promising that the Ministry would continue to monitor water channels in areas that are densely populated.

Representative by Oluwole Majekodunmi, the Commissioner for Education, Science and Technology, Abayomi Arigbagbu, admonished school administrators to ensure that hygienic foods are served to the pupils and students.

Arigbagbu encouraged school administrators to sensitise their pupils and students on proper hygiene and regular washing of hands among others.

25 cholera cases recorded in Ogun, one dead

Continue Reading

Health

NAFDAC alerts public to fake B-GAG syrup

Published

on

NAFDAC alerts public to fake B-GAG syrup

The National Agency for Food and Drug Administration and Control (NAFDAC) has notified Nigerians about the illegal production and sale of unregistered B-GAG mist pot CIT syrup.

The alert is contained in a public in notice No. 023/2024, issued by the agency’s Director-General, Prof. Mojisola Adeyeye, in Abuja on Sunday.

The unregistered product is alleged to have been sold by a company named Babban Gida Agalawa General Enterprises.

According to the statement, the product, being presented in a pet bottle, was discovered during a surveillance operation carried out by the NAFDAC Post Marketing Surveillance Directorate Officers in Maiduguri, Borno, and Keffi, Nasarawa States.

It said that the product was found to be without NAFDAC registration number and a misleading label.

NAFDAC in the statement said that illegal marketing of medicines or counterfeit medicines posed a risk to public health.

Adeyeye noted that without compliance with regulatory provisions the safety, quality, and efficacy of such products were not guaranteed.

READ ALSO:

The agency gave the batch number of the fake product as: 0070, manufacturing date as: 01/02/2024, as well as the expiring date as: 01/02/2027.

Adeyeye also gave the address of the manufacturer as No. 883/884 Western Bypass Ring Road, Kumbosto Local Government, Kano State.

Adeyeye further said that NAFDAC Zonal Directors and State Coordinators had been directed to carry out surveillance with a view to mopping up the illegal products within the zones and states.

She advised consumers and caregivers to avoid the use of the product, adding that all medical products must be obtained from authorised and licensed suppliers.

Adeyeye said that products’ authenticity and physical condition should be carefully checked before buying.

She also advised healthcare professionals and consumers to report any suspicion of either the sale of substandard and falsified medicines or medical devices to the nearest NAFDAC office.

Adeyeye called on the public to report any adverse reaction to NAFDAC on 0800-162-3322 or via email: sf.alert@nafdac.gov.ng.

She encouraged healthcare professionals and patients to report adverse events or side effects related to the use of medicinal products through NAFDAC E-reporting platforms.

The e-reporting platforms, according to her are: www.nafdac.gov.ng, the Med- safety application available for download on android, and IOS stores or via e-mail on pharmacovigilance@nafdac.gov.ng.

She said the notice about the product would be uploaded on the World Health Organisation (WHO) Global Surveillance and Monitoring System (GSMS).

NAFDAC alerts public to fake B-GAG syrup

Continue Reading

Health

Breakthrough as HIV prevention drug records 100% success

Published

on

Breakthrough as HIV prevention drug records 100% success

A promising new HIV prevention drug called lenacapavir has shown 100 percent efficacy in a clinical trial among adolescent girls and young women in South Africa and Uganda.

The twice-yearly injection was found to be superior to daily Truvada, the current standard for pre-exposure prophylaxis (PrEP). This is according to Gilead Sciences, the developer of lenacapavir.

In a release signed by Kay Marshall, Senior Communications Advisor for AVAC, the organization welcomes the groundbreaking results of the PURPOSE 1 study which enrolled over 5,300 cisgender adolescent girls and young women ages between the age of 16 and 26 in South Africa and Uganda.

The study evaluated injectable lenacapavir for PrEP and daily oral emtricitabine/tenofovir alafenamide (F/TAF) for PrEP.

An independent data and safety monitoring board (DSMB), at a scheduled review of the trial data, found the regimen to be safe and highly effective, with no infections seen among trial participants who received injectable lenacapavir.

Regulation

HIV prevention advocate and AVAC’s executive director, Mitchell Warren hails the lenacapavir trial results as a significant advancement. He emphasized the potential of long-acting injectables to increase adherence, improve access, and reduce strain on healthcare systems.

READ ALSO:

“We expect to see a timeline that takes into account a full analysis of PURPOSE 1 data and the coming data from PURPOSE 2 from Gilead as soon as possible, and we urge regulatory agencies to prepare to fast track regulatory review.

“We look forward to working with civil society partners, Gilead, international donors, normative agencies and national governments to ensure that this groundbreaking HIV prevention option is made available as quickly as possible and that we don’t squander this opportunity to drive down new HIV infections,” Warren said.

The Regional Stakeholder Engagement Manager for AVAC, and a member of the PURPOSE 1 Global Community Advisory Group, Nandisile Sikwana said, “We are incredibly excited about this result, especially about what it can mean for women in Africa. We applaud Gilead’s commitment to Good Participatory Practice in this and the other PURPOSE studies.

“While we wait for full data from the study, including adherence data of oral F/TAF, it is imperative that planning for rollout of lenacapavir be accelerated. We know that even with the most ambitious timeline, it will take time for lenacapavir to be rolled out”.

Continue Reading

Trending